TROP-2 expression in papillary thyroid cancer: A preliminary cyto-histological study

Cytopathology

Volumn 26, Issue 5, 2015, Pages 303-311

  Addati, T ^a   Achille, G ^a   Centrone, M ^a   Petroni, S ^a   Popescu, O ^a   Russo, S ^a   Grammatica, L ^a   Simone, G ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Cytology; Fine needle aspirate; FNA; HBME 1; Immunocytochemistry; Thyroid carcinoma; TROP 2

Indexed keywords

HECTOR BATTIFORA MESOTHELIAL ANTIGEN 1; PEPTIDES AND PROTEINS; TROP 2 PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; HBME-1 ANTIGEN; TACSTD2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CYTODIAGNOSIS; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; TISSUE SECTION; TROPHOBLAST; ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; CARCINOMA; CYTODIAGNOSIS; FEMALE; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; THYROID GLAND; THYROID TUMOR; YOUNG ADULT;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BIOPSY, FINE-NEEDLE; CARCINOMA; CELL ADHESION MOLECULES; CYTODIAGNOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84942102909     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12196     Document Type: Article

References (40)

1. Cibas ES, Alexander EK, Benson CB et al. Indications for thyroid FNA and pre-FNA requirements: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:390-9.
2. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid 2009;19:1159-65.
3. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
4. Piana S, Ragazzi M, Tallini G et al. Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph nodes metastases: report of 3 cases, with morphological and molecular analysis. Hum Pathol 2013;44:556-65.
5. Barroeta JE, Baloch ZW, Lal P et al. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 2006;17:225-34.
6. Vriens MR, Weng J, Suh I et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 2011;17:3426-32.
7. Keutgen XM, Filicori F, Crowley MJ et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 2012;18:2032-8.
8. Cochand-Priollet B, Dahan H, Laloi-Michelin M et al. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid 2011;21:1067-73.
9. Hashimoto K, Morimoto A, Kato M et al. Immunocytochemical analysis for differential diagnosis of thyroid lesions using liquid-based cytology. Nagoya J Med Sci 2011;73:15-24.
10. De Matos PS, Ferreira AP, de Oliveira Facuri F et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005;47:391-401.
11. Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 2010;5:9.
12. Filie AC, Asa SL, Geisinger KR et al. Utilization of ancillary studies in thyroid fine needle aspirates: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:438-41.
13. Finley DJ, Zhu B, Barden B et al. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 2004;240:425-36.
14. Rossi ED, Martini M, Capodimonti S et al. BRAF (V600E) mutation analysis on liquid based cytology processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid carcinoma. Cancer Cytopathol 2013;121:291-7.
15. Poller DN, Glaysher S. BRAF V600 co-texting is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy. Cytopathology 2014;25:155-9.
16. Johnson SJ, Hardy SA, Roberts C et al. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology 2014;25:146-54.
17. Lanzillotta SG, Grammatica L, Paradiso A, Simone G. BRAF in papillary thyroid carcinoma. Cell Oncology 2007;29:269-77.
18. Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010;73:113-28.
19. Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC. The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid 2009;19:1215-23.
20. Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998;76:671-6.
21. Alberti S, Miotti S, Stella M et al. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma 1992;11:539-45.
22. Shimada H, Nakashima K, Ochiai T et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol 2004;26:77-86.
23. Zhang L, Zhou W, Velculescu VE et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
24. Mühlmann G, Spizzo G, Gostner J et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009;62:152-8.
25. Fong D, Moser P, Krammel C et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008;99:1290-5.
26. Fong D, Spizzo G, Gostner JM et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Modern Pathol 2008;21:186-91.
27. Fang YJ, Lu ZH, Wang GQ et al. Elevated expressions of MMP7, TROP2, and surviving are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009;24:875-84.
28. Miotti S, Canevari S, Ménard S et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987;9:297-303.
29. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004;89:3214-23.
30. Fadda G, Basolo F, Bondi A et al. Cytological classification of thyroid nodules. Proposal of the SIAPEC-IAP Italian Consensus Working Group. Pathologica 2010;102:405-6.
31. Ratour J, Polivka M, Dahan H et al. Diagnosis of follicular lesions of undetermined significance in fine needle aspirations of thyroid nodules. J Thyroid Res 2013;2013: Article 250347, 6 pages.
32. Alexander EK, Kennedy GC, Baloch ZW et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012;367:705-15.
33. Barden CB, Shister KW, Zhu B et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 2003;9:1792-800.
34. Baloch ZW, Fleisher S, Li Volsi VA et al. Diagnosis of "follicular neoplasm" a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 2002;26:41-4.
35. Lee SR, Jung CK, Kim TE et al. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of ras mutation testing. Thyroid 2013;23:1416-22.
36. Addati T, Centrone M, Petroni S et al. TROP-2 expression and V600E BRAF mutation in papillary thyroid carcinoma, Abstract. Pathologica 2013;105:267-8.
37. Trerotola M, Cantanelli P, Guerra E et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 2013;32:222-33.
38. Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009;1796:309-14.
39. El-Sawki K, Bellone S, Cocco E et al. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM specific immunotherapy with human monoclonal antibody adecatumumab. Mol Cancer Ther 2010;9:57-66.
40. Raji R, Guzzo F, Carrara L et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to h RS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res 2011;30:106.